The Latest Analyst Ratings for bluebird bio
Portfolio Pulse from Benzinga Insights
In the last quarter, bluebird bio (NASDAQ:BLUE) received 3 somewhat bullish, 2 indifferent, and 1 somewhat bearish analyst ratings. The average 12-month price target for the stock is $7.0, with a high of $10.00 and a low of $3.00, increasing by 10.58% over the past month.
June 01, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
bluebird bio (NASDAQ:BLUE) received mixed analyst ratings in the last quarter, with an average 12-month price target of $7.0, which has increased by 10.58% over the past month.
The mixed analyst ratings for bluebird bio indicate that there is no clear consensus on the stock's short-term direction. The average 12-month price target has increased by 10.58% over the past month, which may suggest some positive sentiment, but the overall ratings remain mixed. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100